research Response of alopecia areata of the beard to oral tofacitinib
Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
Search
for
Sort by
Research
60-90 / 1000+ results research 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.
research BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.
research A systematic review of acute telogen effluvium, a harrowing post‐COVID‐19 manifestation
COVID-19 can cause a type of hair loss that usually starts 74 days after infection, affecting mostly women, but most patients eventually recover.
research Tinea capitis mimicking dissecting cellulitis of the scalp: a histopathologic pitfall when evaluating alopecia in the post‐pubertal patient
A fungal infection can look like a different scalp condition in teens, leading to wrong treatment until proper tests are done.
research Alopecia Associated with Fluconazole Therapy
Taking fluconazole for fungal infections might cause hair loss after about 3 months.
research A dermatologist's visit to the community: An intriguing perspective
A community dermatology event in Delhi showed a high need for follow-up and awareness about skin conditions.
research Tinea capitis due to Trichophyton soudanense mimicking bacterial folliculitis
A man's scalp infection, mistaken for bacterial, was actually a rare fungal infection treated successfully with antifungal medication.
research KERION MICROSPORICUM WITH HEMATOGENOUS AND ECTOGENOUS MICROSPORIDS
A rare scalp infection in a child developed into a kerion with additional skin symptoms.
research Black dot tinea capitis caused by trichophyton rubrum in an adult female presenting with cicatricial alopecia
A woman's scalp infection caused by a fungus led to permanent hair loss and was hard to treat but responded to a specific antifungal.
research Severe form of keratitis–ichthyosis–deafness (KID) syndrome associated with septic complications
Infants with severe KID syndrome may be more prone to serious infections and need close monitoring.
research Time of onset and duration of post-COVID-19 acute telogen effluvium
Hair loss from COVID-19 usually starts around 45 days after infection and lasts about 47.5 days.
research Comprehensive Study of Drug-Induced Pruritus Based on Adverse Drug Reaction Report Database
Certain drugs, especially those for eyes, bacterial infections, imaging tests, and skin conditions, are more likely to cause itching, with differences seen across gender, age, and weight.
research Trichotillomania in a young male complicated by tinea capitis associated with Cryptococcus laurentii and Candida parapsilosis
The boy's hair loss was due to a hair-pulling disorder, not just a fungal infection.
research Diffuse telogen effluvium: Etiology, pathogenesis, and a comprehensive approach to treatment
Diffuse telogen alopecia is temporary hair loss treated by addressing the root cause and improving scalp health.
research Cyclophosphamide: As bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases
Cyclophosphamide has serious side effects, but long-term follow-up can help manage risks.
research Halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapy
Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.
research Corona With Lyme: A Long COVID Case Study
The study concludes that long COVID recovery involves time, various treatments, and a strong patient-provider relationship.
research Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
research Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis
Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.
research Chemotherapy for children with medulloblastoma
Chemotherapy may help with survival in children with medulloblastoma, but more research is needed.
research The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
research Concurrent Eosinophilic Pneumonitis and Diffuse Alveolar Hemorrhage Secondary to Naproxen
Naproxen can cause serious lung issues, but high-dose aspirin might be safer.
research Cardiovascular Toxicities of Androgen Deprivation Therapy
ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.
research Janus kinase inhibitors in dermatology: A systematic review
JAK inhibitors help with skin conditions but need more research on dosing and safety.
research Efficacy and safety of dual-targeted therapy for refractory inflammatory bowel disease: a retrospective case series from three tertiary general hospitals in China
Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.
research ZAOSTRZENIA NIEWYDOLNOŚCI ODDECHOWEJ- PRZYCZYNY I POSTĘPOWANIE
COPD flare-ups worsen life quality and increase hospital visits and costs.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
research Characteristics and Outcomes of Patients on Tofacitinib for Alopecia Areata or Rheumatoid Arthritis: A Retrospective Cohort Study
Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.